PRESS RELEASE published on 02/20/2026 at 21:37, 7 months 23 days ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 7 months 24 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
BRIEF published on 12/09/2025 at 14:55, 10 months 6 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 10 months 6 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 10 months 6 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 11 months 4 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 11 months 4 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 11 months 10 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 11 months 10 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 1 year ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
Published on 10/16/2026 at 05:55, 1 hour 38 minutes ago Collective Metals Announces Private Placement of Hard Dollar and Flow-Through Units
Published on 10/16/2026 at 02:10, 5 hours 23 minutes ago Nova Scotia Silver Explorer TruSilver Metals Corp. Anticipates TSXV Trading Under "TAG" on October 27
Published on 10/16/2026 at 01:45, 5 hours 48 minutes ago Faraday Copper Closes the Acquisition of the San Manuel Project in Arizona and Mobilizes Drill Rigs
Published on 10/16/2026 at 01:30, 6 hours 3 minutes ago LNG Energy Group Announces Closing of Second Tranche of Private Placement
Published on 10/15/2026 at 23:08, 8 hours 25 minutes ago ACCESS Newswire to Present at the 20th Annual LD Micro Main Event XX - Tuesday October 20, 2026 - 11:00AM PT (2:00PM ET)
Published on 10/16/2026 at 07:00, 32 minutes ago PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
Published on 10/15/2026 at 22:30, 9 hours 2 minutes ago Porsche Mission S: the essence of the sports car reinterpreted
Published on 10/15/2026 at 20:30, 11 hours 2 minutes ago Nordex Group reports strong preliminary Q3/2026 results and raises EBITDA margin guidance for full year 2026
Published on 10/15/2026 at 20:28, 11 hours 4 minutes ago EQS-Adhoc: Nordex SE: Nordex Group reports strong preliminary Q3/2026 results and raises EBITDA margin guidance for full year 2026
Published on 10/15/2026 at 18:50, 12 hours 43 minutes ago September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
Published on 10/15/2026 at 17:45, 13 hours 48 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
